Advice
following a full submission
atomoxetine (Strattera®) is accepted for use within NHS Scotland.
Indication under review: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme. The presence of symptoms that were pre-existing in childhood should be confirmed.
Short term studies in adults have shown that atomoxetine improves symptoms of ADHD compared to placebo.
The economic case for atomoxetine has been demonstrated for a treatment duration of one year.
Download detailed advice157KB (PDF)
Medicine details
- Medicine name:
- atomoxetine (Strattera)
- SMC ID:
- 909/13
- Indication:
- Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme. The presence of symptoms that were pre-existing in childhood should be confirmed.
- Pharmaceutical company
- Lilly UK
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 November 2013